论文部分内容阅读
1文献来源Engert A,Haverkamp H,Kobe C,et al.Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma(HD15 trial):A randomised,open-label,phase 3 non-inferiority trial[J].Lancet,2012,379(9828):1791-1799.2证据水平1b。3背景采用ABVD方案治疗晚期霍奇金淋巴瘤(Hodgkin lymphoma,HL)患者,5年无进展生存率(progression-free survival,PFS)仅为65%~70%,8疗程增强BEACOPP方案能显著提高疗效,但毒性
1 Sources Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): A randomized, open-label, phase 3 non-inferiority trial [ J] .Lancet, 2012, 379 (9828): 1791-1799.2 Level of Evidence 1b. 3 Background The 5-year progression-free survival (PFS) was only 65% -70% in the patients with advanced Hodgkin lymphoma (HL) treated with the ABVD regimen. The BEACOPP regimen was significantly improved after 8 cycles of treatment Efficacy, but toxicity